Clinuvel Pharmaceuticals Share Price and Company Fundamentals



Price
$39.19
Change
0.020 (0.051%)
52 week
19.63 - 44.67

Last traded: Yesterday at 5:10 AM

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Key Metrics

PE ratio

83.64

PB ratio

20.26

Dividend yield

0.06%

Beta

0.41

Market cap

$2.00B

Enterprise value

$1.92B

Company profile

Primary activitiesClinuvel Pharmaceuticals Ltd. is a leading and innovative Australian company focused on the development of SCENESSE¿ (afamelanotide), its proprietary first-in-class drug, as a photoprotective in a range of UV and light related skin disorders and as a repigmentation therapy in the common skin disorder vitiligo.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.clinuvel.com
Mailing address535 Bourke Street Level 11 Melbourne VIC 3000 Australia
Phone / Fax61 3 9660 4900 / 61 3 9660 4909
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

More: Clinuvel Pharmaceuticals Dividend history, yield and payout ratio

Dividend yield

0.06%

Dividend amount

$0.03

Payout ratio

5.17%

Clinuvel Pharmaceuticals paid $0.03 dividend and the ex-dividend date was 02 Sept 2021.The dividend payout ratio is 5.17%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.CUV dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

CUV's forward dividend amount is $0.03 and the forward dividend yield is 0.06%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Oct 2021, following are the company executives and directors listed on Clinuvel Pharmaceuticals.

NameTitleAgeTotal Pay
Dr. Philippe Jacques Wolgen M.B.A., M.D., MBACEO, MD & Director572.67M
Mr. Darren M. KeamyCFO & Company Sec.47363.88k
Dr. Dennis J. WrightChief Scientific Officer302k
Mr. Lachlan HayDirector of Global Operations
Mr. Malcolm BullHead of Investor Relations

Profitability and management effectiveness

Profit margin

51.54%

Operating margin

58.83%

Return on assets

18.56%

Return on equity

28.96%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Clinuvel Pharmaceuticals is 2.00B and its enterprise value is 1.92B. The enterprise value to revenue ratio of CUV is 39.99.

The CUV's stocks Beta value is 0.41 making it 59% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Clinuvel Pharmaceuticals (CUV)

Clinuvel Pharmaceuticals (ASX:CUV) Frequently Asked Questions

1. What is Clinuvel Pharmaceuticals's Stock Symbol?

Clinuvel Pharmaceuticals trades on ASX under the ticker symbol "CUV".

2. What is Clinuvel Pharmaceuticals's stock price today?

One share of CUV stock can currently be purchased for approximately $39.19.

3. How can I contact Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals's mailing address is 535 Bourke Street Level 11 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9660 4900.

4. What is Clinuvel Pharmaceuticals's official website?

The official website of Clinuvel Pharmaceuticals is http://www.clinuvel.com.

5. Which share registry manages Clinuvel Pharmaceuticals's stock?

Clinuvel Pharmaceuticals's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.